FY2027 EPS Estimates for Roche Decreased by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Analysts at Erste Group Bank cut their FY2027 EPS estimates for shares of Roche in a research report issued on Wednesday, March 4th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.48 per share for the year, down from their prior forecast of $3.50. The consensus estimate for Roche’s current full-year earnings is $2.81 per share.

A number of other research analysts have also issued reports on the company. Deutsche Bank Aktiengesellschaft raised Roche from a “sell” rating to a “hold” rating in a report on Tuesday, November 11th. JPMorgan Chase & Co. raised shares of Roche from an “underweight” rating to a “neutral” rating in a research note on Monday, December 8th. TD Cowen restated a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. The Goldman Sachs Group raised shares of Roche from a “sell” rating to a “hold” rating in a report on Thursday, January 15th. Finally, Barclays upgraded shares of Roche from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Roche currently has a consensus rating of “Hold” and a consensus price target of $57.00.

Roche Stock Up 2.2%

RHHBY opened at $55.39 on Monday. Roche has a 52 week low of $34.75 and a 52 week high of $60.85. The business has a 50 day moving average price of $55.93 and a two-hundred day moving average price of $48.69. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72.

Institutional Investors Weigh In On Roche

A number of large investors have recently added to or reduced their stakes in the business. Boston Common Asset Management LLC lifted its position in shares of Roche by 1.9% in the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock valued at $15,049,000 after acquiring an additional 6,720 shares in the last quarter. Altrius Capital Management Inc raised its stake in Roche by 4.0% in the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock valued at $8,290,000 after purchasing an additional 7,659 shares during the last quarter. Bard Financial Services Inc. lifted its holdings in Roche by 1.3% in the 3rd quarter. Bard Financial Services Inc. now owns 138,650 shares of the company’s stock valued at $5,797,000 after purchasing an additional 1,800 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Roche by 1.1% during the 2nd quarter. Rhumbline Advisers now owns 108,480 shares of the company’s stock worth $4,422,000 after purchasing an additional 1,228 shares during the last quarter. Finally, Meritage Portfolio Management purchased a new stake in shares of Roche during the fourth quarter worth about $4,372,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.